Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)

Next Previous
Trial Profile

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Delamanid (Primary) ; Isoniazid (Primary) ; Pyridoxine
  • Indications Pulmonary tuberculosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PHOENIx MDR-TB

Most Recent Events

  • 23 Apr 2025 Status changed from recruiting to active, no longer recruiting.
  • 14 Nov 2024 According to an ACTG media release, data from this study was presented in an oral presentation titled "High Prevalence of Fluoroquinolone Resistance and katG Mutations in Adult Index Patients in a Multinational MDR-TB Prevention Trial", at The Union Conference on Lung Health 2024, in Bali, Indonesia.
  • 14 Nov 2024 The PHOENIx MDR-TB and CLO-FAST studies are sponsored by the NIH's National Institute of Allergy and Infectious Diseases (NIAID, which also funds ACTG) under award numbers UM1 AI068636, UM1 AI107716, and UM1 AI068634.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top